

N A T Hamdy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7971038/publications.pdf>

Version: 2024-02-01

131
papers

6,565
citations

66315

42
h-index

71651

76
g-index

139
all docs

139
docs citations

139
times ranked

5893
citing authors

#	ARTICLE	IF	CITATIONS
1	Determinants of Quality of Life in Adult Patients with Chronic Non-Bacterial Osteomyelitis (CNO) of the Sternocostoclavicular Region (SCCH): A Dutch Single Center Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 1852.	1.0	1
2	Identification of Compound Heterozygous Variants in LRP4 Demonstrates That a Pathogenic Variant outside the Third Î²-Propeller Domain Can Cause Sclerosteosis. <i>Genes</i> , 2022, 13, 80.	1.0	3
3	Increased Prevalence of Malignancies in Fibrous Dysplasia/McCune-Albright Syndrome (FD/MAS): Data from a National Referral Center and the Dutch National Pathology Registry (PALGA). <i>Calcified Tissue International</i> , 2021, 108, 346-353.	1.5	10
4	Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1437-1446.	1.8	14
5	Chronic Nonbacterial Osteomyelitis of the Sternocostoclavicular Region in Adults: A Single Center Dutch Cohort Study. <i>JBMR Plus</i> , 2021, 5, e10490.	1.3	7
6	X-linked hypophosphatemia: The medical expert's challenges and the patient's concerns on their journey with the disease. <i>Archives De Pediatrie</i> , 2021, 28, 612-618.	0.4	5
7	Pathophysiology of Vascular Calcification and Bone Loss: Linked Disorders of Ageing?. <i>Nutrients</i> , 2021, 13, 3835.	1.7	19
8	Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders: An Updated Practical Tool for Physicians and Patients. <i>Hormone Research in Paediatrics</i> , 2020, 93, 182-196.	0.8	42
9	Patients With Isolated Craniofacial Dysplasia Report Better Quality of Life Compared With Those With Craniofacial Dysplasia and Extracranial Involvement. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2020, 36, 292-297.	0.4	4
10	Added Value of Impact Microindentation in the Evaluation of Bone Fragility: A Systematic Review of the Literature. <i>Frontiers in Endocrinology</i> , 2020, 11, 15.	1.5	28
11	Denosumab in Patients With Fibrous Dysplasia Previously Treated With Bisphosphonates. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6069-6078.	1.8	49
12	Prevalence and Clinical Features of Mazabraud Syndrome. <i>Journal of Bone and Joint Surgery - Series A</i> , 2019, 101, 160-168.	1.4	21
13	Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 139.	1.2	149
14	Pain in fibrous dysplasia: relationship with anatomical and clinical features. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2019, 90, 401-405.	1.2	19
15	Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1169-1179.	1.1	20
16	Illness Perceptions are Associated with Quality of Life in Patients with Fibrous Dysplasia. <i>Calcified Tissue International</i> , 2018, 102, 23-31.	1.5	17
17	Increased Risk of Breast Cancer at a Young Age in Women with Fibrous Dysplasia. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 84-90.	3.1	39
18	Low wintertime pre-diagnostic vitamin D status is associated with an increased risk of internal malignancies in kidney transplant recipients. <i>Photochemical and Photobiological Sciences</i> , 2018, 17, 1946-1955.	1.6	4

#	ARTICLE	IF	CITATIONS
19	Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. <i>Nature Reviews Endocrinology</i> , 2018, 14, 476-500.	4.3	224
20	Passive Coping Strategies Are Associated With More Impairment In Quality Of Life In Patients With Fibrous Dysplasia. <i>Calcified Tissue International</i> , 2018, 103, 469-475.	1.5	14
21	Individualized approach to the surgical management of fibrous dysplasia of the proximal femur. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 72.	1.2	20
22	What Is the Role of Allogeneic Cortical Strut Grafts in the Treatment of Fibrous Dysplasia of the Proximal Femur?. <i>Clinical Orthopaedics and Related Research</i> , 2017, 475, 786-795.	0.7	26
23	Bone material strength index as measured by impact microindentation is altered in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2017, 176, 339-347.	1.9	51
24	CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4534-4540.	1.8	65
25	Impact Microindentation: Consistency of Serial Measurements and Alterations in Patients With Paget's Disease of the Tibia. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 2375-2380.	3.1	16
26	Value and potential limitations of vertebral fracture assessment (VFA) compared to conventional spine radiography: experience from a fracture liaison service (FLS) and a meta-analysis. <i>Osteoporosis International</i> , 2017, 28, 2955-2965.	1.3	26
27	Bone material strength index as measured by impact microindentation is low in patients with fractures irrespective of fracture site. <i>Osteoporosis International</i> , 2017, 28, 2433-2437.	1.3	47
28	High prevalence of autoimmune disease in the rare inflammatory bone disorder sternocostoclavicular hyperostosis: survey of a Dutch cohort. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 20.	1.2	9
29	Determinants of impaired quality of life in patients with fibrous dysplasia. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 80.	1.2	24
30	Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 264-276.	3.1	70
31	Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma. <i>Endocrine</i> , 2016, 54, 642-647.	1.1	8
32	High prevalence of secondary factors for bone fragility in patients with a recent fracture independently of BMD. <i>Archives of Osteoporosis</i> , 2016, 11, 12.	1.0	30
33	RE: Serum vit D levels and response to molecular subtypes in breast cancer. <i>Breast</i> , 2016, 27, 186.	0.9	0
34	Vitamin D (25-OH D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01). <i>Breast</i> , 2016, 25, 69-74.	0.9	29
35	Bone Material Strength as Measured by Microindentation In Vivo Is Decreased in Patients With Fragility Fractures Independently of Bone Mineral Density. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2039-2045.	1.8	91
36	Aandoeningen van de bij schildklier. <i>Bijblijven (Amsterdam, Netherlands)</i> , 2015, 31, 258-270.	0.0	0

#	ARTICLE	IF	CITATIONS
37	Changes in Bone Mineral Density in Newly Diagnosed Testicular Cancer Patients After Anticancer Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4101-4108.	1.8	17
38	No Association Between BMD and Prevalent Vertebral Fractures in Liver Transplant Recipients at Time of Screening Before Transplantation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3677-3685.	1.8	17
39	Effects of up to 15 years of recombinant human <sc>GH</sc> (rh<sc>GH</sc>) replacement on bone metabolism in adults with Growth Hormone Deficiency (<sc>GHD</sc>): The Leiden Cohort Study. <i>Clinical Endocrinology</i> , 2014, 81, 727-735.	1.2	29
40	Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). <i>Annals of Oncology</i> , 2014, 25, 998-1004.	0.6	33
41	Longitudinal Changes in BMD and Fracture Risk in Orthotopic Liver Transplant Recipients Not Using Bone-Modifying Treatment. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1763-1769.	3.1	30
42	Serum Dickkopf 1 Levels in Sclerostin Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E252-E256.	1.8	45
43	The role of vitamin D in human fracture healing: a systematic review of the literature. <i>Bone</i> , 2014, 64, 288-297.	1.4	102
44	Long-term treatment of osteoporotic women with bisphosphonates does not impair the response to subsequently administered intravenous pamidronate. <i>Osteoporosis International</i> , 2013, 24, 2353-2357.	1.3	1
45	Van Buchem disease: Clinical, biochemical, and densitometric features of patients and disease carriers. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 848-854.	3.1	102
46	Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. <i>British Journal of Cancer</i> , 2013, 109, 60-67.	2.9	77
47	A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years. <i>Rheumatology International</i> , 2013, 33, 2231-2239.	1.5	29
48	Progression of Vertebral Fractures Despite Long-Term Biochemical Control of Acromegaly: A Prospective Follow-up Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4808-4815.	1.8	90
49	Reply: "Comment on Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors". <i>British Journal of Cancer</i> , 2013, 109, 2503-2504.	2.9	1
50	THERAPY OF ENDOCRINE DISEASE: Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. <i>European Journal of Endocrinology</i> , 2013, 168, R45-R53.	1.9	248
51	NEOZOTAC: Efficacy results from a phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer (BC) "A Dutch Breast Cancer Trialists" Group (BOOG) study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1028-1028.	0.8	2
52	Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism?. <i>European Journal of Endocrinology</i> , 2012, 166, 55-60.	1.9	23
53	Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus. <i>European Journal of Endocrinology</i> , 2012, 166, 711-716.	1.9	67
54	Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover. <i>Bone</i> , 2012, 51, 153-157.	1.4	55

#	ARTICLE	IF	CITATIONS
55	Circulating Sclerostin Levels Are Decreased in Patients with Endogenous Hypercortisolism and Increase after Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1953-E1957.	1.8	47
56	Low-energy fractures of the humeral shaft and bisphosphonate use. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1425-1431.	3.1	8
57	The Role of Sclerostin in the Pathophysiology of Sclerosing Bone Dysplasias. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2012, 10, 108-116.	1.3	21
58	Initial results of the treatment of diffuse sclerosing osteomyelitis of the mandible with bisphosphonates. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2011, 39, 65-68.	0.7	54
59	Atypical fractures and bisphosphonate therapy: A cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. <i>Bone</i> , 2011, 48, 966-971.	1.4	164
60	Limitations of Tc99m-MIBI SPECT Imaging Scans in Persistent Primary Hyperparathyroidism. <i>World Journal of Surgery</i> , 2011, 35, 128-139.	0.8	41
61	Patients with sclerosteosis and disease carriers: Human models of the effect of sclerostin on bone turnover. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 2804-2811.	3.1	117
62	Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma. <i>Modern Pathology</i> , 2011, 24, 688-697.	2.9	59
63	High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. <i>European Journal of Endocrinology</i> , 2011, 164, 475-483.	1.9	125
64	Effects of Alendronate on Bone Quality and Remodeling in Glucocorticoid-Induced Osteoporosis: A Histomorphometric Analysis of Transiliac Biopsies. <i>Journal of Bone and Mineral Research</i> , 2010, 15, 754-762.	3.1	95
65	Challenges and Pitfalls in the Management of Parathyroid Carcinoma: 17-Year Follow-Up of a Case and Review of the Literature. <i>Hormones and Cancer</i> , 2010, 1, 205-214.	4.9	22
66	The psychological burden of an initially unexplained illness: patients with sternocostoclavicular hyperostosis before and after delayed diagnosis. <i>Health and Quality of Life Outcomes</i> , 2010, 8, 97.	1.0	9
67	Glucocorticoids are not always deleterious for bone. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2796-2800.	3.1	27
68	<i>APC</i> mutations are associated with increased bone mineral density in patients with familial adenomatous polyposis. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2624-2632.	3.1	22
69	Diagnostic delay in sternocostoclavicular hyperostosis: Impact on various aspects of quality of life. <i>Arthritis Care and Research</i> , 2010, 62, 251-257.	1.5	24
70	The role of selective venous sampling in the management of persistent hyperparathyroidism revisited. <i>European Journal of Endocrinology</i> , 2010, 163, 945-952.	1.9	30
71	No recurrence of sporadic primary hyperparathyroidism when cure is established 6 months after parathyroidectomy. <i>European Journal of Endocrinology</i> , 2010, 162, 399-406.	1.9	15
72	Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. <i>European Journal of Endocrinology</i> , 2010, 163, 833-837.	1.9	89

#	ARTICLE	IF	CITATIONS
73	Prevalence of Vertebral Fractures Independent of BMD and Anticancer Treatment in Patients with Testicular Germ Cell Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4933-4942.	1.8	12
74	Atypical fractures of the femur and bisphosphonate therapy. <i>Bone</i> , 2010, 47, 169-180.	1.4	248
75	Strontium ranelate improves bone microarchitecture in osteoporosis. <i>Rheumatology</i> , 2009, 48, iv9-iv13.	0.9	43
76	Is parathyroidectomy safe and beneficial in the elderly?. <i>Nature Reviews Endocrinology</i> , 2009, 5, 422-423.	4.3	16
77	Sclerostin in Mineralized Matrices and van Buchem Disease. <i>Journal of Dental Research</i> , 2009, 88, 569-574.	2.5	117
78	Low bone mineral density in adult patients with moderate to severe atopic dermatitis. <i>British Journal of Dermatology</i> , 2009, 161, 1248-1254.	1.4	41
79	Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis. <i>Bone</i> , 2009, 44, 766-771.	1.4	7
80	Similarities and differences of responses to intravenous (I.V.) bisphosphonate treatment (pamidronate) in postmenopausal and steroid-induced osteoporosis. <i>Bone</i> , 2008, 42, S78.	1.4	0
81	Normal Growth and Muscle Dysfunction in X-Linked Hypophosphatemic Rickets Associated with a Novel Mutation in the PHEX Gene. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 1386-1389.	1.8	19
82	SOST/Sclerostin. , 2008, , 139-152.		6
83	Denosumab: RANKL inhibition in the management of bone loss. <i>Drugs of Today</i> , 2008, 44, 7.	0.7	39
84	A patient with persistent primary hyperparathyroidism due to a second ectopic adenoma. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 311-315.	2.9	3
85	Calcium and Bone Metabolism Pre- and Post-Kidney Transplantation. <i>Endocrinology and Metabolism Clinics of North America</i> , 2007, 36, 923-935.	1.2	11
86	Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria. <i>European Journal of Clinical Investigation</i> , 2007, 37, 435-453.	1.7	673
87	Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis. <i>Current Opinion in Investigational Drugs</i> , 2007, 8, 299-303.	2.3	32
88	Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor. <i>Journal of Internal Medicine</i> , 2006, 260, 177-182.	2.7	89
89	Ileum resection is the most predictive factor for osteoporosis in patients with Crohn's disease. <i>Osteoporosis International</i> , 2006, 17, 535-542.	1.3	33
90	Osteoprotegerin as a potential therapy for osteoporosis. <i>Current Rheumatology Reports</i> , 2006, 8, 50-54.	2.1	12

#	ARTICLE	IF	CITATIONS
91	The Effects of Thyrotropin-Suppressive Therapy on Bone Metabolism in Patients with Well-Differentiated Thyroid Carcinoma. <i>Thyroid</i> , 2006, 16, 583-591.	2.4	111
92	Limited Rescue of Osteoclast-Poor Osteopetrosis After Successful Engraftment by Cord Blood From an Unrelated Donor. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 2264-2270.	3.1	16
93	Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn's disease. <i>Osteoporosis International</i> , 2005, 16, 1727-1730.	1.3	18
94	Osteoprotegerin as a potential therapy for osteoporosis. <i>Current Osteoporosis Reports</i> , 2005, 3, 121-125.	1.5	11
95	Long-term maintenance of the anabolic effects of GH on the skeleton in successfully treated patients with acromegaly. <i>European Journal of Endocrinology</i> , 2005, 152, 53-60.	1.9	23
96	Bone Mineral Density in Sclerosteosis; Affected Individuals and Gene Carriers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6392-6395.	1.8	162
97	Severe hypophosphatemic osteomalacia in hormone-refractory prostate cancer metastatic to the skeleton: natural history and pitfalls in management. <i>Bone</i> , 2005, 36, 1-5.	1.4	12
98	Osteoprotegerin as a potential therapy for osteoporosis. <i>Current Osteoporosis Reports</i> , 2005, 3, 121-125.	1.5	2
99	Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. <i>Clinical Endocrinology</i> , 2004, 60, 568-575.	1.2	49
100	Long-term follow-up study on bone mineral density and fractures after simultaneous pancreas-kidney transplantation. <i>Kidney International</i> , 2004, 66, 2070-2076.	2.6	38
101	Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 958-963.	3.3	19
102	Relationships Between Pharmacokinetics and Rate of Bone Turnover After Intravenous Bisphosphonate (Olpadronate) in Patients With Paget's Disease of Bone. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 868-875.	3.1	31
103	Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy. <i>Bone</i> , 2003, 33, 831-838.	1.4	21
104	A potential role for the mast cell in the pathogenesis of idiopathic osteoporosis in men. <i>Bone</i> , 2002, 31, 556-561.	1.4	61
105	Estramustine phosphate combined with orchidectomy as first-line therapy in patients with prostate carcinoma. <i>Cancer</i> , 2002, 94, 2596-2601.	2.0	0
106	A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. <i>European Journal of Clinical Pharmacology</i> , 2002, 57, 883-890.	0.8	66
107	Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 494-498.	3.3	39
108	The flare in alkaline phosphatase activity post-orchidectomy predicts which patient may benefit from early chemotherapy in metastatic prostate cancer. <i>Prostate</i> , 2002, 50, 119-124.	1.2	10

#	ARTICLE	IF	CITATIONS
109	Osteoporosis and Bone Marrow Mastocytosis: Dissociation of Skeletal Responses and Mast Cell Activity During Long-Term Bisphosphonate Therapy. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 567-569.	3.1	33
110	Daily Oral Pamidronate in Women and Men With Osteoporosis: A 3-Year Randomized Placebo-Controlled Clinical Trial With a 2-Year Open Extension. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 1057-1064.	3.1	69
111	Management of Malignancy-Associated Hypercalcemia. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2002, 1, 65-76.	1.3	2
112	Strategies for Management of Prostate Cancer-Related Bone Pain. <i>Drugs and Aging</i> , 2001, 18, 899-911.	1.3	21
113	The palliative management of skeletal metastases in prostate cancer: Use of bone-seeking radionuclides and bisphosphonates. <i>Seminars in Nuclear Medicine</i> , 2001, 31, 62-68.	2.5	54
114	Additional Beneficial Effects of Alendronate in Growth Hormone (GH)-Deficient Adults with Osteoporosis Receiving Long-Term Recombinant Human GH Replacement Therapy: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3079-3085.	1.8	25
115	Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton. <i>Cancer</i> , 2000, 88, 3047-3053.	2.0	52
116	Bone Histomorphometric Evaluation of Pamidronate Treatment in Clinically Manifest Osteoporosis. <i>Osteoporosis International</i> , 1999, 9, 489-493.	1.3	41
117	Skeletal Effects of Two Years of Treatment with Low Physiological Doses of Recombinant Human Growth Hormone (GH) in Patients with Adult-Onset GH Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2143-2148.	1.8	70
118	Long-Term Effects of Bisphosphonates on the Growing Skeleton: Studies of Young Patients with Severe Osteoporosis. <i>Medicine (United States)</i> , 1997, 76, 266-283.	0.4	236
119	The Flare in Serum Alkaline Phosphatase Activity After Orchiectomy: A Valuable Negative Prognostic Index for Progression-Free Survival in Prostatic Carcinoma. <i>Journal of Urology</i> , 1996, 156, 122-126.	0.2	16
120	The spectrum of renal bone disease. <i>Nephrology Dialysis Transplantation</i> , 1995, 10, 14-18.	0.4	58
121	Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. <i>BMJ: British Medical Journal</i> , 1995, 310, 358-363.	2.4	279
122	Malignancy-associated hypercalcaemia: resolution of controversies over vitamin D metabolism by a pathophysiological approach to the syndrome. <i>Clinical Endocrinology</i> , 1994, 41, 251-256.	1.2	20
123	A comparison of the acute effects of subcutaneous and intranasal calcitonin. <i>Clinical Science</i> , 1990, 78, 215-219.	1.8	29
124	Broadband ultrasound attenuation in the os calcis: relationship to bone mineral at other skeletal sites. <i>Clinical Science</i> , 1990, 78, 227-233.	1.8	108
125	Treatment of paget's disease of bone with aminohydroxybutylidene bisphosphonate. <i>Journal of Bone and Mineral Research</i> , 1990, 5, 483-491.	3.1	69
126	Calcium metabolism and myeloma and the treatment of hypercalcemia. <i>Hematological Oncology</i> , 1988, 6, 115-117.	0.8	1

#	ARTICLE	IF	CITATIONS
127	Diphosphonates and phosphate homoeostasis in man. <i>Clinical Science</i> , 1988, 74, 607-612.	1.8	32
128	Effects of intravenous etidronate disodium on skeletal and calcium metabolism. <i>American Journal of Medicine</i> , 1987, 82, 55-70.	0.6	64
129	Aminohexane diphosphonate in the treatment of paget' s disease of bone. <i>Journal of Bone and Mineral Research</i> , 1987, 2, 273-279.	3.1	42
130	Additional Beneficial Effects of Alendronate in Growth Hormone (GH)-Deficient Adults with Osteoporosis Receiving Long-Term Recombinant Human GH Replacement Therapy: A Randomized Controlled Trial. , 0, .		10
131	Diagnosis and management of pseudohypoparathyroidism and related disorders: first international consensus statement. <i>Endocrine Abstracts</i> , 0, , .	0.0	1